Abstract
Interferons are first immunomodulatory molecules that have been shown to display a wide range of applications due to their antiviral, antibacterial, antitumor, and inflammatory activities. Natural and recombinant interferons are among most common biologic therapeutics worldwide. Interferon inducers, however, are less known and have been mostly developed and used in former socialist countries. Despite the fact that they are virtually unknown to the Western world, they represent a substantial market share of modern pharmacopoeia in former socialist republics. This review provides a brief description of most popular interferon inducers including Amyxin, Amizon, Anandin, Arbidol, Blasten, Cycloferon, Galavit, Groprinosine, Hepon, Immunoxel, Dzherelo, Kagocel, Larifan, Ligfol, Likopid, Mebavin, MIGI-KLP, V-5 Immunitor, SCV-07, Milife, Neovir, Poludan, Ragocin, Ridostin, Thymogen and Savratz, some of which were in use for several decades for the same clinical indications as for interferons. The variety and choice offered by the pharmaceutical industry behind the former “iron curtain” certainly deserves the appreciation, familiarity and application prospects for medical and research investigators worldwide.
Current Pharmaceutical Design
Title: Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Volume: 15 Issue: 11
Author(s): Dmytro S. Silin, Oksana V. Lyubomska, Feliks I. Ershov, Valeriy M. Frolov and Galyna A. Kutsyna
Affiliation:
Abstract: Interferons are first immunomodulatory molecules that have been shown to display a wide range of applications due to their antiviral, antibacterial, antitumor, and inflammatory activities. Natural and recombinant interferons are among most common biologic therapeutics worldwide. Interferon inducers, however, are less known and have been mostly developed and used in former socialist countries. Despite the fact that they are virtually unknown to the Western world, they represent a substantial market share of modern pharmacopoeia in former socialist republics. This review provides a brief description of most popular interferon inducers including Amyxin, Amizon, Anandin, Arbidol, Blasten, Cycloferon, Galavit, Groprinosine, Hepon, Immunoxel, Dzherelo, Kagocel, Larifan, Ligfol, Likopid, Mebavin, MIGI-KLP, V-5 Immunitor, SCV-07, Milife, Neovir, Poludan, Ragocin, Ridostin, Thymogen and Savratz, some of which were in use for several decades for the same clinical indications as for interferons. The variety and choice offered by the pharmaceutical industry behind the former “iron curtain” certainly deserves the appreciation, familiarity and application prospects for medical and research investigators worldwide.
Export Options
About this article
Cite this article as:
Silin S. Dmytro, Lyubomska V. Oksana, Ershov I. Feliks, Frolov M. Valeriy and Kutsyna A. Galyna, Synthetic and Natural Immunomodulators Acting as Interferon Inducers, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846847
DOI https://dx.doi.org/10.2174/138161209787846847 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Natural Products as a Paradigm for the Treatment of Coxsackievirus - induced Myocarditis
Current Topics in Medicinal Chemistry How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Current Proteomics Photosensitizer Nanoparticles for Photodynamic Therapy
Current Bioactive Compounds The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications
Current Molecular Pharmacology Imaging Features of Carcinosarcoma Arising from Adenofibroma of the Uterus: A Case Report
Current Medical Imaging Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology A Single Fas Gene Mutation Changes Lupus Onset, Severity, Location, and Molecular Abnormalities in Mice
Current Molecular Medicine Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Patented HIV-1 Integrase Inhibitors (1998-2005)
Recent Patents on Anti-Infective Drug Discovery Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery The Long-Term Impact of Early Adversities on Psychiatric Disorders: Focus on Neuronal Plasticity
Current Pharmaceutical Design Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Drug Resistance in Renal Tumors of Childhood
Current Pharmaceutical Biotechnology The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery A Roadmap of Cancer: From the Historical Evidence to Recent Salivary Metabolites-based Nanobiosensor Diagnostic Devices
Current Metabolomics and Systems Biology (Discontinued) Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents